Mangrove Partners’s Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 CANO.WS Stock Holding History

Mangrove Partners’s Portfolio CANO.WS Stock Details CANO.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-308,663	Closed	-$3.91M	–	564
2021 Q3	$3.91M	Buy	+308,663	New	+$1.16M	0.35%	89

Other funds holding CANO.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Mangrove Partners's CANO.WS Position: Q4 2021 in Review

Mangrove Partners sold out of Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 (CANO.WS) in Q4 2021, closing a stake of 308,663 shares — an estimated $3.91M sold.

Mangrove Partners first reported a position in CANO.WS in Q3 2021 and held it in 1 quarter. The position peaked at $3.91M in Q3 2021. 33 funds tracked by Wall St. Rank hold CANO.WS as of Q4 2021.

Mangrove Partners reported no remaining Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 position as of Q4 2021 after selling out during the quarter.
Mangrove Partners sold 308,663 Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 shares in Q4 2021, an estimated $3.91M.
Mangrove Partners first reported a position in Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 in Q3 2021 and held it in 1 quarter.
Mangrove Partners's Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 position peaked at $3.91M in Q3 2021.
33 funds tracked by Wall St. Rank held Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 as of Q4 2021.

Based on Mangrove Partners's 13F filing for Q4 2021, filed 14 Feb 2022.